Jeff Solomon, TD Cowen president, joins 'Money Movers' to discuss the underlying tone of the AI drama this week, what to ...
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report). The company’s shares closed yesterday at $10.92. According to ...
TD Cowen raised the firm’s price target on FIS (FIS) to $87 from $86 and keeps a Hold rating on the shares. The firm said the continuation of sturdy macro indicators support steady Payments ...
Investing.com -- TD Cowen downgraded Celsius Holdings (NASDAQ:CELH) to Hold and slashed its price target for the stock to $29 from $40 in a note Wednesday, citing slowing sales growth, intensifying ...
Celsius Holdings (NASDAQ:CELH) swung lower in early trading on Wednesday after TD Cowen downgraded the energy drink stock to a Hold rating after having it set at Buy. Notably, the firm's retail ...
Investing.com -- TD Cowen downgraded Celsius Holdings (NASDAQ:CELH) to Hold and slashed its price target for the stock to $29 from $40 in a note Wednesday, citing slowing sales growth ...
On Wednesday, TD Cowen reaffirmed its confidence in Netflix (NASDAQ:NFLX) stock, raising the price target to $1,150 from the previous $1,000 while maintaining a Buy rating. Currently trading at $ ...
In a report released on January 17, Thomas Fitzgerald CFA from TD Cowen maintained a Buy rating on Delta Air Lines (DAL – Research Report), with a price target of $90.00. The company’s shares ...
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report). The company’s shares opened today at $1.42. According to TipRanks ...
On Tuesday, Forte Biosciences Inc. (NASDAQ:FBRX), a biotech company with a market capitalization of approximately $100 million, received a new Buy rating from TD Cowen, as the firm began its ...
A curated selection of the top 10 logistics and supply chain stories from 2024, reflecting key trends and themes identified by LM Group News Editor Jeff Berman—offering insights beyond popularity ...
Fintel reports that on January 17, 2025, TD Cowen upgraded their outlook for Salesforce (NYSE:CRM) from Hold to Buy. Analyst Price Forecast Suggests 26.18% Upside As of December 23, 2024 ...